Publications

AR alterations and therapy resistance in prostate cancer

Posted in General News, Publications Published by Bethan Warman 16 May 2019

AR alterations and therapy resistance in prostate cancer

Recent findings from a study published in JAMA Oncology have identified genetic markers within blood samples which may indicate whether patients with prostate cancer will respond to hormonal therapies. The study may represent an important step forward for the development of more personalised treatments for advanced prostate cancer.

Eliminating cancer stem cells: Scientists discover a novel drug target for aggressive blood cancer

Posted in General News, Publications Published by Bethan Warman 25 April 2019

Eliminating cancer stem cells: Scientists discover a novel drug target for aggressive blood cancer

Research published today in Cell Stem Cell has discovered a protein which drives an aggressive form of blood cancer, acute myeloid leukaemia (AML). Inactivation of this protein selectively compromises leukaemic cells while promoting normal blood cell functions.

Phase I clinical trial finds combination therapy to be well-tolerated in patients with high-grade gliomas

Posted in General News, Publications Published by Bethan Warman 29 March 2019

Phase I clinical trial finds combination therapy to be well-tolerated in patients with high-grade gliomas

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients. The trial used a treatment combination of ADI-PEG20, pemetrexed and cisplatin, which showed encouraging efficacy in patients with recurrent high-grade gliomas (HGGs), a disease for which little progress has been made over the last few decades.

Using flies to reveal mechanisms of cancer development- Q&A with Dr Ribeiro

Posted in General News, Interviews, Publications Published by Bethan Warman 27 February 2019

Using flies to reveal mechanisms of cancer development- Q&A with Dr Ribeiro

Dr Paulo Ribeiro is a Senior Lecturer and Group Leader in our Centre for Tumour Biology. We asked him some questions about his most recent publication, which set out to identify new regulators of cancer development using the fruit fly Drosophila as a model organism.

Tackling tumour scar tissue could be key to treating pancreatic cancer

Posted in General News, Publications Published by Administrator 11 February 2019

Tackling tumour scar tissue could be key to treating pancreatic cancer

The first study in the world to take a detailed look at scar tissue in human pancreatic cancer has revealed a range of different scar tissue types that could help clinicians predict which patients will respond best to particular treatments.

Immune cells found as accomplices in melanoma spread

Posted in General News, Publications Published by Bethan Warman 31 January 2019

Immune cells found as accomplices in melanoma spread

A new study published today in Cell has revealed that aggressive melanoma cells are able to manipulate the immune system to their advantage. As a result, immune cells that are supposed to recognise and destroy cancer cells actually behave differently and support the growth and spread of the tumour.

‘The neighbouring effect’: Centrosomal abnormalities drive invasion of surrounding cells

Posted in General News, Publications Published by Bethan Warman 19 November 2018

‘The neighbouring effect’: Centrosomal abnormalities drive invasion of surrounding cells

Centrosomal amplification, a particular change that occurs within some cancer cells, has been shown to drive the invasion of neighbouring cancer cells in a recent study by researchers from the BCI, led by Dr Susana Godinho, and the Francis Crick Institute.

Killer cell immunotherapy shows promise for advanced pancreatic cancer

Posted in General News, Publications Published by Bethan Warman 01 November 2018

Killer cell immunotherapy shows promise for advanced pancreatic cancer

A new approach to treating pancreatic cancer using 'educated killer cells' has shown promise, according to early research from the BCI. The new cell-based immunotherapy, which has not yet been tested in humans with pancreatic cancer, led to mice being completely cancer-free.

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

Posted in General News, BCI on the Road, Publications Published by Bethan Warman 22 October 2018

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

New research led by Barts Cancer Institute and St Bartholomew’s Hospital has provided new hope for people with an aggressive type of breast cancer. The phase 3 clinical trial has shown that by using a combination of immunotherapy and chemotherapy, the body’s own immune system can be tuned to attack triple-negative breast cancer, extending survival by up to ten months.

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Posted in General News, Publications Published by Bethan Warman 17 October 2018

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC). The phase 1 clinical trial, led by Prof Peter Schmid, Centre Lead for BCI’s Centre for Experimental Cancer Medicine, is the first to report the long-term safety and efficacy of the drug for mTNBC, and may represent significant steps forward for treatment of this disease.

[12 3 4  >>  
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.